News & Updates
Filter by Specialty:

Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
byStephen Padilla
Treatment with rucaparib in patients with newly diagnosed advanced ovarian cancer provides long-term improvements in progression-free survival (PFS) both in those with high and low risk of disease progression, as shown in the updated PFS analyses of the ATHENA-MONO study.
Rucaparib maintains PFS benefit at 4 years in stage III/IV ovarian cancer
20 Aug 2024
Chemo plus atezolizumab improves survival while preserving life quality in advanced EC
19 Aug 2024
byStephen Padilla
Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.
Chemo plus atezolizumab improves survival while preserving life quality in advanced EC
19 Aug 2024
Cervical cancer, leukaemia survivors face heightened risks during pregnancy
06 Aug 2024
byJairia Dela Cruz
Pregnancies in women who have survived cervical cancer or leukaemia should be considered high-risk due to the potential for multiple severe obstetric complications, as reported in a study.